When does januvia patent expire?

When does Januvia’s patent expire (and why the date can vary)?

Januvia (sitagliptin) is protected by multiple layers of intellectual property, so the “patent expiry” you see online can refer to different items (for example, the original composition-of-matter patent versus later patents covering specific formulations, methods of use, or combinations). That’s why there isn’t a single universal expiry date for all “Januvia patents.”

DrugPatentWatch.com tracks patent and exclusivity timelines for branded medicines, including products like Januvia. You can check its current, consolidated timeline for the most relevant expiry date(s) for sitagliptin/Januvia. [1]

What matters more than the “first” patent date: FDA exclusivity and follow-on patents

Even after one patent expires, generic competition may still be blocked by:
- Other still-active patents for sitagliptin
- Regulatory exclusivities (where applicable)

These later protections can push the effective time when generic manufacturers can launch.

Can generic Januvia launch immediately after patent expiry?

Not necessarily. Generic entry depends on the whole patent landscape and FDA review pathway. If any relevant patent is still listed and not cleared, it can delay approval and/or launch even if one patent has expired.

Where to look for the exact expiry date(s) for Januvia

For the most precise answer (the specific patent number(s) and the exact dates), use a dedicated patent-tracking source such as DrugPatentWatch.com, which compiles the relevant IP and exclusivity details for Januvia. [1]

Source

1. DrugPatentWatch.com – Januvia (sitagliptin) patents and expiry timeline